Using artificial intelligence (AI) to specialize treatment for patients with different kinds of cancer can be a boon to clinicians looking to personalize their care.

Guideline-directed medical therapy used with remote monitoring can potentially reduce hospitalization in patients with heart failure with ejection fraction.

New methods of testing tissue and plasma beyond next-generation sequencing (NGS) could be used to deliver the best therapeutic options for patients with cancer.

Marcus Flores, PharmD, BCPS, BCOP, discusses the vital role of pharmacists in multidisciplinary cancer care, exploring collaboration, patient-centered strategies, and AI.

Ken Cohen, MD, FACP, discusses how new cognitive assessment tools are improving Alzheimer disease diagnosis.

Susan Escudier, MD, FACP, of Texas Oncology, suggests actionable insights to improve equitable access to patient cancer care

Incorporating tools that gauge social determinants of health can improve patient access to cancer care, explained Susan Escudier, MD.

Ken Cohen, MD, FACP, discusses how clinicians can support patients after a cognitive screening to identify meaningful next steps.

Susan Escudier, MD, discusses the practical implications of financial barriers for patients with cancer accessing oncology care.

Kavita Nair, PhD, FAAN, discusses the rising global burden of neurodegenerative diseases.

Andrew Wolf, MD, discusses the growing costs, treatment advances, and geographic disparities in multiple sclerosis care.

Tara Carlisle, MD, PhD, University of Colorado, discusses how coordinated care efforts and frequent safety monitoring are transforming early Alzheimer disease management.

Ken Cohen, MD, FACP, discusses the importance of expanding cognitive screening for seniors.

Experts discuss the importance of initiating blinatumomab treatment for acute lymphoid leukemia in academic centers for optimal patient care.

Kelley L. Julian, PharmD, BCOP, discusses optimizing myeloma care, addressing barriers in access to intravenous immunoglobulin and innovative therapies at Huntsman Cancer Institute.

David Rometo, MD, reflects on the sustainability of incremental weight loss programs and aggressive diets.

David Rometo, MD, weighs various weight loss treatments, their success, and sustainability.

David Rometo, MD, of UPMC, addresses stigma surrounding obesity and group setting weight loss intervention therapies and how consults benefit patients.

Clinician's role in breast cancer care and access with reproductive and urinary oncologist Lakshminarayanan Nandagopal, MD

Hope Krebill of the Masonic Cancer Alliance at the University of Kansas Medical Center outlines patient navigation models that improve outcomes and reduce missed appointments.

Advancements in breast cancer care and treatments with reproductive and urinary oncologist Lakshminarayanan Nandagopal, MD.

Hope Krebill, MSW, BSN, RN, discusses the challenges rural hospitals face in delivering therapies like CAR T and bispecifics.

From proactive recruitment to academic-community partnerships, Hope Krebill highlights ways to improve clinical trial participation.

Cardiologists, nephrologists, and payers met in Scottsdale, Arizona, on August 26, 2025, to share insights on how team members can work together, empowered by data, to achieve value-based management of cardio-renal-metabolic syndrome.

Experts in cardiometabolic conditions gathered in Aurora, Colorado, on August 19, 2025, to discuss the methods available to prevent cardiovascular events.

On July 9, 2025, experts from across Providence Health & Services gathered in Garden Grove, California, for in-depth discussions on patient-centered care for chronic diseases.

Oranus Mohammadi, MD, outlines how antibody-drug conjugates are transforming breast cancer treatment across subtypes and discusses her approach to sequencing high-cost targeted therapies within payer and clinical practice constraints.

Matias Sanchez, MD, a hematologist-oncologist at University of Illinois Health, discussed the latest advancements in value-based multiple myeloma care, including minimal residual disease strategies and innovative targeted therapies.

Oranus Mohammadi, MD, discusses the emerging applications of circulating tumor DNA (ctDNA) in breast cancer care and emphasizes the importance of clear communication to help patients navigate uncertain or anxiety-provoking biomarker test results.

Joanne Mortimer, MD, FACP, FASCO, discusses the practical applications and limitations of circulating tumor DNA (ctDNA) testing in breast cancer, highlighting its role in guiding targeted therapy, challenges in patient communication and payer coverage, and unique barriers for male patients.